ATHN Related Analyst Ratings
-
Sterne Agee Resumes athenahealth (ATHN) at Neutral
-
Goldman Sachs Resumes athenahealth (ATHN) at Neutral
-
Raymond James Upgrades athenahealth (ATHN) to Strong Buy
-
Jefferies Lifts PT on Cerner (CERN) to $110
-
No Reason to Get Excited about Athenahealth (ATHN), Thinks Oppenheimer
-
Raymond James Downgrades athenahealth (ATHN) to Outperform
-
Sterne Agee Upgrades athenahealth (ATHN) to Neutral
-
Leerink Swann Upgrades athenahealth (ATHN) to Outperform on Tailwinds
-
Analysts Leery as athenahealth (ATHN) Investor Day Kicks Off
-
JMP Securities Starts athenahealth (ATHN) at Market Outperform
-
Raymond James Upgrades athenahealth (ATHN) to Strong Buy
-
Is the PSS/McKesson Deal a Curse or a Blessing in Disguise for athenahealth (ATHN)?
-
Oppenheimer Pours Salt on athenahealth's (ATHN) Wounds
-
Jefferies Downgrades athenahealth (ATHN) to Underperform
-
Avondale Partners Downgrades athenahealth (ATHN) to Market Perform
-
First Analysis Downgrades athenahealth (ATHN) to Equal Weight
-
Jefferies Maintains a 'Hold' on athenahealth (ATHN); Raising Estimates & Price Target
-
UBS Maintains a 'Sell' on athenahealth (ATHN); Decent Quarter, But Valuation Too High
-
Citi Upgrades athenahealth (ATHN) to Buy
-
Wells Fargo Maintains an 'Outperform' on athenahealth (ATHN); Triple-Barrel Deal Significantly Improves Visibility
-
ISI Group Starts athenahealth (ATHN) at Overweight
-
Sterne Agee Downgrades athenahealth (ATHN) to Underperform
-
Wells Fargo Starts athenahealth at Outperform; Three Reasons Why ATHN Will Gain Market Share
-
Lazard Starts ATHN, CERN, QSII, MDAS at Buy, MDRX, OMCL, CPSI, EHTH at Neutral, EPOC at Sell
-
Morgan Stanley Upgrades athenahealth (ATHN) to Equalweight
-
Auriga Reiterates a 'Sell' on athenahealth (ATHN); Q1 Demonstrates Progress
-
Jefferies Boosts Price Target on Athenahealth Inc. (ATHN)
-
UPDATE - Auriga Downgraded athenahealth (ATHN) to Sell; Suggests Taking Profits as Things Get Cloudy
-
Auriga Downgrades athenahealth (ATHN) to Sell
-
Sterne Agee Downgrades athenahealth (ATHN) to Neutral
-
UBS Maintains a 'Sell' on athenahealth (ATHN); Raising Numbers on Suspected Conservatism
-
Jefferies Raises athenahealth (ATHN) Price Target to $58 after Q4, Keeps Hold Rating
-
Sterne Agee Starts athenahealth (ATHN) at Buy
-
UBS Maintains a 'Sell' on athenahealth (ATHN); 2012 EPS Guidance Disappoints
-
Jefferies Cuts PT on athenahealth (ATHN) to $50; Says Lowered Outlook Comes from Unexpected Places
-
Oppenheimer Upgrades athenahealth (ATHN) to Perform
-
Leerink Swann Upgrades athenahealth (ATHN) to Outperform; Strong Growth Still Expected
-
Avondale Partners Starts athenahealth (ATHN) at Market Outperform
-
Jefferies Starts athenahealth (ATHN) at Hold
-
UBS Maintains a 'Sell' on athenahealth (ATHN); High Growth But Little Leverage
-
Caris & Co. Downgrades athenahealth (ATHN) to Average
-
JPMorgan Downgrades athenahealth (ATHN) to Underweight
-
Auriga maintains a 'Hold' on athenahealth (ATHN); Vulnerable in a Volatile Market at Current Valuation
-
Cowen Starts athenahealth (ATHN) at Neutral, Shares Down 3.49%
-
Goldman Sachs Lifts Numbers On athenahealth (ATHN), But Is Neutral On Valuation
-
Auriga Reiterates a 'Hold' on athenahealth (ATHN); Strong Q2 Results, Guidance; Raise Target
-
UBS Maintains a 'Sell' on athenahealth (ATHN); Investments May Pressure 2H EPS Growth
-
Goldman Sachs Rates athenahealth (ATHN) a Neutral
-
Auriga Reiterates a 'Hold' on athenahealth (ATHN); UH Deal is Nice, but Maybe Too Much Hullabaloo
-
Caris & Co. Upgrades athenahealth (ATHN) to Above Average
Back to ATHN Stock Lookup
